A drug used with protein-bound paclitaxel to treat triple-negative breast cancer that cannot be removed by surgery, is locally advanced, or has spread to other parts of the body. It is used in adults whose cancer has the PD-L1 protein. It is also used with bevacizumab, paclitaxel, and carboplatin to treat non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body and has not been treated. It is used in adults whose cancer does not have a mutation (change) in the EGFR or ALK genes. Atezolizumab is also used to treat certain types of NSCLC and urothelial cancer (a type of bladder cancer) that are locally advanced or have spread to other parts of the body and cannot be treated with or have gotten worse during or after treatment with anticancer drugs that included platinum. It is also being studied in the treatment of other types of cancer. Atezolizumab binds to a protein called PD-L1, which is found on some cancer cells. Atezolizumab may block this protein and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Tecentriq.